Translating Our Research
Here at the MRC Weatherall Institute of Molecular Medicine, we foster a strong culture of innovation.
Over the years, our researchers have spun out a variety of companies from their discoveries, including Immunocore and MiroBio.
In 2022, we also opened the Therapy Acceleration Lab, which conducts studies for clinical trials.
Therapy Acceleration Lab (TAL)
The TAL analyses human samples from national and international clinical trials of novel targeted therapies that maximise patient impact, transform understanding of disease biology and dissect mechanisms of action of therapies and mechanisms of response.
Spinout Companies
© PopTika/Shutterstock.com
World-leading research from scientists at the MRC Weatherall Institute of Molecular Medicine has been developed into commercial ventures with the aim of translating our discoveries into clinics and benefiting patients.
Innovation News from the MRC WIMM
35 Years of the MRC WIMM
23 October 2024
In 1989, Sir David Weatherall founded the Institute of Molecular Medicine to bridge the gap between basic science and clinical medicine. To mark 35 years since the MRC WIMM opened its labs, we're looking back on some of our highlights and achievements.
Yellowstone Biosciences spinout launches to advance cutting-edge cancer therapies
15 July 2024
Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford.
Professor Simon Davis appointed as RDM’s first Entrepreneurship Lead
5 October 2023
Simon Davis, Professor of Molecular Immunology in the MRC TIDU at the MRC WIMM, has been appointed as RDM’s first Entrepreneurship Lead.
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing
19 October 2022
The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.